Wall Street brokerages forecast that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will report earnings of $0.72 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.73 and the lowest estimate coming in at $0.71. Eagle Pharmaceuticals reported earnings of $0.95 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 24.2%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $3.46 per share for the current financial year, with EPS estimates ranging from $3.38 to $3.59. For the next year, analysts anticipate that the company will report earnings of $4.11 per share, with EPS estimates ranging from $3.10 to $5.11. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.28. Eagle Pharmaceuticals had a return on equity of 21.38% and a net margin of 17.67%. The firm had revenue of $49.80 million for the quarter, compared to analyst estimates of $47.03 million. During the same period last year, the company earned $0.55 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis.
NASDAQ:EGRX traded up $1.21 during mid-day trading on Friday, reaching $50.78. The company’s stock had a trading volume of 1,886 shares, compared to its average volume of 200,453. The company has a current ratio of 4.12, a quick ratio of 3.89 and a debt-to-equity ratio of 0.21. Eagle Pharmaceuticals has a twelve month low of $36.03 and a twelve month high of $85.66. The firm has a market cap of $729.77 million, a price-to-earnings ratio of 24.14 and a beta of 1.57.
In other news, Director Douglas L. Braunstein sold 159,223 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $56.81, for a total value of $9,045,458.63. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Scott Tarriff sold 24,975 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $50.15, for a total value of $1,252,496.25. Following the completion of the transaction, the chief executive officer now owns 1,500,202 shares in the company, valued at $75,235,130.30. The disclosure for this sale can be found here. Company insiders own 28.20% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. New York State Teachers Retirement System raised its holdings in shares of Eagle Pharmaceuticals by 2.2% in the 1st quarter. New York State Teachers Retirement System now owns 9,677 shares of the specialty pharmaceutical company’s stock worth $489,000 after purchasing an additional 208 shares during the period. Campbell Newman Asset Management Inc. raised its holdings in shares of Eagle Pharmaceuticals by 2.5% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 9,437 shares of the specialty pharmaceutical company’s stock worth $476,000 after purchasing an additional 234 shares during the period. Carillon Tower Advisers Inc. raised its holdings in shares of Eagle Pharmaceuticals by 0.6% in the 1st quarter. Carillon Tower Advisers Inc. now owns 53,496 shares of the specialty pharmaceutical company’s stock worth $2,701,000 after purchasing an additional 300 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Eagle Pharmaceuticals by 156.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 642 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 392 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Eagle Pharmaceuticals by 1.4% in the 4th quarter. Legal & General Group Plc now owns 29,746 shares of the specialty pharmaceutical company’s stock worth $1,190,000 after purchasing an additional 416 shares during the period. Institutional investors own 94.96% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Featured Article: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.